Safety, Tolerability and Pharmacokinetics of Single Subcutaneous Doses of BI 3034701 in Healthy Male Volunteers (Part A) and of Multiple Rising Subcutaneous Doses in Otherwise Healthy Male and Female Volunteers With Obesity/Overweight (Part B)
Latest Information Update: 01 Jul 2025
At a glance
- Drugs BI 3034701 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 25 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 14 May 2025 Planned End Date changed from 30 Sep 2025 to 5 Oct 2025.
- 14 May 2025 Planned primary completion date changed from 30 Sep 2025 to 5 Oct 2025.